CardioFocus Inc.'s HeartLight laser endoscopic atrial fibrillation ablation system met its primary endpoint according to one-year data from the firm's U.S. pivotal trial
presented May 15 at the Heart Rhythm Society's annual conference in Boston. The results were presented by co-principal investigator Vivek Reddy of the Mount Sinai School of Medicine in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?